Association between ICAs, MRI markers of CSVD and MetS severity Z-score
| Model 1 | Model 2 | |||
| β/OR (95% CI) | P value | β/OR (95% CI) | P value | |
| Presence of ICAS | 1.88 (1.50 to 2.34) | <0.001 | 1.75 (1.39 to 2.21) | <0.001 |
| CSVD markers | ||||
| WMH volume | 0.16 (0.07 to 0.24) | <0.001 | 0.11 (0.01 to 0.20) | 0.02 |
| Presence of lacunes | 1.40 (1.14 to 1.72) | 0.002 | 1.28 (1.03 to 1.59) | 0.03 |
| Presence of CMBs | 0.98 (0.79 to 1.22） | 0.86 | 0.93 (0.74 to 1.16) | 0.51 |
| EPVS in basal ganglia | 0.97 (0.86 to 1.11) | 0.69 | 0.96 (0.84 to 1.09) | 0.51 |
| EPVS in white matter | 1.13 (1.00 to 1.27) | 0.06 | 1.09 (0.96 to 1.23) | 0.21 |
Results are from logistic regression analysis for ICAS, the prevalence of lacunes, CMBs and EPVS; ORs (95% CI) are shown. Multiple regression analysis was performed for WMHs volume; β (95% CI) represents the change in the log-transformed WMHs volume per SD increase in MetS score. The log-transformed WMHs volume was used in the regression analysis. Model 1: adjusted for age and sex. Model 2: adjusted as in model 1+use of antihyperlipidaemic medication, use of antihypertensive medication, use of antidiabetic medication and current smoking status.
CMBs, cerebral microbleeds; CSVD, cerebral small vessel disease; EPVS, enlarged perivascular spaces; ICAS, intracranial atherosclerotic stenosis; MetS, metabolic syndrome; WMHs, white matter hyperintensities.